ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors - Trial NCT06332170
Access comprehensive clinical trial information for NCT06332170 through Pure Global AI's free database. This Phase 1 trial is sponsored by Hansoh BioMedical R&D Company and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 610 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hansoh BioMedical R&D Company
Timeline & Enrollment
Phase 1
May 30, 2024
May 30, 2028
Primary Outcome
Maximum tolerated dose (MTD) for combination-treatments
Summary
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to
 B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to
 investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in
 combination with other anti-cancer agents in patients with advanced solid tumor patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06332170
Non-Device Trial